Determine the Institute's strategy and research policy. Optimize human resources and finances. Promote information exchange with external parties to ensure the sustainable development of the Institute.

Development of new therapeutic targets based on cancer biology and creation of new candidates for anti-cancer drugs.

Development of new drugs for drug-resistant pathogenic bacteria, exploratory research of microbial metabolites, and unique libraries consisting of newly isolated microorganisms and natural products.

Exploration of novel bioactive compounds and their modes of action study empowered by natural product chemical biology. Development of novel antifungal agents.

Research on the pathogenesis of human cancers based on bacterial and viral infections and their prevention and treatment. Research on the development of new antiviral drugs.

Analyzing biological phenomena such as autophagy using structural biology methods, elucidating disease mechanisms and drug design in collaboration with other groups.

Research on exploring microbial resources for anticancer compounds and the application of microorganisms in environmental/ecological science.

Development of animal models that play crucial roles in understanding intractable human diseases and developing therapeutic modalities against them.

Generating medical lead based on synthetic approach, and development of catalytic asymmetric reactions.

Analysis of molecular structures of bioactive substances or synthetic compounds by various analytical instruments

Responsible for managing and disseminating information on research achievements, inventions, and contracts. Management of the Hamao Umezawa Memorial Museum.